Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
INM
Inmune Bio
INMB · NASDAQ · Biological Products, (No Diagnostic Substances)
No open-market purchase by an insider of Inmune Bio was filed in the last 90 days. The latest on record was on Sep 30, 2024.
How often do Inmune Bio insiders buy and sell shares?
Since 2019, Inmune Bio insiders reported 39 open-market purchases and 23 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2024.
Who is selling Inmune Bio stock?
No open-market sale by an insider of Inmune Bio (INMB) was filed with the SEC in the last 90 days.
Do members of Congress trade INMB?
No trade in Inmune Bio (INMB) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Other Biological Products, (No Diagnostic Substances) companies
−44.5% (−$0.663) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.49 on Nov 20, 2025 to $0.827 on Nov 20, 2026 (−44.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$0.50$1.50$2.00$2.50$3.00$0.827
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Boca Raton, Fl.
Last 12 months
−44.5%
S&P 500 +5.7% over the same dates
Market value
$29.3M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.66M shares sold short (7.5% of shares outstanding), −7.9% vs the previous count, 14.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2019
Insiders of Inmune Bio reported 39 open-market purchases and 23 sales since 2019; purchases in 5 different years, most recently 2024.
Year
Bought
Sold
2024
$903K8×8 trades
—
2023
$65K2×2 trades
$110K1×1 trade
2022
$109K3×3 trades
—
2021
$34K1×1 trade
$4.11M21×21 trades
2020
—
$1.01M1×1 trade
2019
$1.31M25×25 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Funds and stakes. Highbridge Capital Management, LLC cut its INMB stake below 5% (5.0%) (filed Nov 16, 2026). (Inmune Bio on OQRO)
Contracts, lobbying and filings. FINRA short interest for INMB on the settlement date of Oct 30, 2026 was 2,658,847 shares (-7.89% on the previous report), about 14.4 days of average volume. In 13F filings for the quarter ended Mar 31, 2026, the largest positions that grew: Modera Wealth Management, LLC (new position); the largest that shrank: Union Bancaire Privee, UBP SA (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Inmune Bio filed a Form 8-K on Sep 14, 2026 (Items 5.02, 8.01) that OQRO classes as: changed a top executive or board member, and reported other company news. The company's own opening sentence of that report reads: "On September 8, 2026, the Board of Directors (the 'Board') of INmune Bio, Inc. (the 'Company') approved to increase the number of directors and to set the number of directors serving on the Board at seven, and, pursuant to the Co..."
Who holds it. 83 funds reported a stake in Inmune Bio in their 13F for Q2 2026. The largest by value: VANGUARD CAPITAL MANAGEMENT LLC (16.3% of the value reported), AQR CAPITAL MANAGEMENT LLC (15.2% of the value reported), BlackRock, Inc. (7.2% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Highbridge Capital Management, LLC cut its INMB stake below 5% (5.0%) (filed Nov 16, 2026).
Contracts, lobbying and filings
FINRA short interest for INMB on the settlement date of Oct 30, 2026 was 2,658,847 shares (-7.89% on the previous report), about 14.4 days of average volume.
In 13F filings for the quarter ended Mar 31, 2026, the largest positions that grew: Modera Wealth Management, LLC (new position); the largest that shrank: Union Bancaire Privee, UBP SA (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Inmune Bio filed a Form 8-K on Sep 14, 2026 (Items 5.02, 8.01) that OQRO classes as: changed a top executive or board member, and reported other company news.
The company's own opening sentence of that report reads: "On September 8, 2026, the Board of Directors (the 'Board') of INmune Bio, Inc. (the 'Company') approved to increase the number of directors and to set the number of directors serving on the Board at seven, and, pursuant to the Co..."
Inmune Bio filed a Form 8-K on Jun 17, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "As noted in Item 5.07 below, on June 16, 2026, INmune Bio Inc. (the 'Company'), held its annual meeting of stockholders (the 'Annual Meeting'), where the stockholders of the Company approved the Company’s Third Amended and Restat..."
Inmune Bio filed a Form 8-K on Dec 3, 2025 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On December 2, 2025, INmune Bio Inc. (the 'Company') and David J. Moss, the Company’s President and Chief Executive entered into an amendment to Mr. Moss’s employment agreement, dated November 26, 2025, to correct a mistake in th..."
Press coverage listed by Finnhub: "INmune Bio, Inc. Q3 2026 Earnings Call Summary" (Yahoo, Nov 6, 2026).
Press coverage listed by Finnhub: "INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update" (Yahoo, Nov 5, 2026).
Press coverage listed by Finnhub: "INmune Bio Q3 2026 Earnings Call Transcript" (Benzinga, Nov 5, 2026).
INMB closed at $1.03 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $1.54 to $1.03, a change of −33.1%.
Who holds it
83 funds reported a stake in Inmune Bio in their 13F for Q2 2026. The largest by value: VANGUARD CAPITAL MANAGEMENT LLC (16.3% of the value reported), AQR CAPITAL MANAGEMENT LLC (15.2% of the value reported), BlackRock, Inc. (7.2% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 19, 2025, INMB is down 45.2% and the index fund is up 4.1%: 49 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much INMB moves
A usual day
±3.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
14.5%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−13.2%Nov 19, 2026
Largest one-day rise
+15.1%May 14, 2026
Deepest fall of the year
−67.1%From the close of Sep 8, 2026 to Nov 20, 2026.
Days of 5% or more
73Out of 252 sessions, in either direction.
Beta 2.6(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
From “Overview”, in the company's words
INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology. Lead Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (“RDEB”) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform. RDEB is a devastating pediatric orphan disease caused by mutations in the COL7A1 gene. This genetic deficiency leads to systemic complications, including highly debilitating skin blistering, chronic non-healing wounds, dysphagia, and failure to thrive.
What the section covers (23 headings)
Overview
Components of Operating Results
Operating Expenses
Research and Development
General and Administrative Expenses
Other income, net
Critical Accounting Estimates
Off-Balance Sheet Arrangements
Licensing and Collaboration Agreements
CORDStrom Clinical Data License Agreement
Xencor
Results of Operations
Comparison of the Years Ended December 31, 2025 and 2024
Revenues
And 9 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Year earlier: $0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $16.3M, at Sep 30, 2026
Net income, last 12 months
−$16.7M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 30, 2025.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Risk factors in the annual report
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 27, 2025. Read the filing
New risk factors in the latest annual report (17 headings)
Limitations on Capital Raising Due to Low Public Float
We are substantially dependent on the success of CORDStrom, and we may never obtain regulatory approval.
Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and conflicts, such as the conflict between Russia and Ukraine and the recent military conflict in the Middle East involving Iran, could make it more difficult for us to access financing and could adversely affect our business and operations.
If we are unable to obtain accelerated approval or other expedited regulatory designations, development and commercialization of our product candidates may be delayed or more costly.
Clinical drug development is lengthy, expensive, and inherently uncertain, and our product candidates may never receive regulatory approval.
Preclinical and early-stage clinical trial results may not predict later results, and interim or preliminary data may change materially.
Even if our product candidates are approved, they may fail to achieve sufficient market acceptance, which could limit revenue and affect our business.
If our product candidates are approved and later found to be less effective than expected or to cause previously unidentified side effects, our business could be materially harmed.
And 9 more headings in the filing.
No longer listed (16 headings from the year before)
We believe we may in some instances be able to secure approval from the FDA or comparable non-U.S. regulatory authorities to use accelerated development pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.
Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidate.
The results of preclinical studies and early-stage clinical trials may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage trials.
Interim top-line and preliminary data from our planned clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
If we experience delays or difficulties in the enrollment of patients in clinical trials, we may not achieve our clinical development on our anticipated timeline, or at all, and our receipt of necessary regulatory approvals could be delayed or prevented.
We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.
We may fail to comply with regulatory requirements.
Legal proceedings (Item 3)
We currently are not a party to any material litigation or other material legal proceedings. We may, from time to time, be subject to legal proceedings and claims arising in the normal course of business.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Even if our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidates may be smaller than we estimate.
And 8 more headings in the filing.
When insiders usually buy
Last results
Oct 30, 2025
More than 30 days ago
Next results, expected
Not announced
Purchases after results
79%
26 of 33 insider purchases since 2019 came within 30 days after a results announcement
From Inmune Bio's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Inmune Bio's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 53.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (12.8% on ATS, 41.0% with other brokers), close to its 26-week average of 53.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: MS POOL (ATS-4) (18.5%), INSTINCT X (15.0%), UBS ATS (13.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.